Journal Article
. 1997 Dec;89(22).
doi: 10.1093/jnci/89.22.1673.

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

B Fisher 1 J Dignam  N Wolmark  A DeCillis  B Emir  D L Wickerham  J Bryant  N V Dimitrov  N Abramson  J N Atkins  H Shibata  L Deschenes  R G Margolese  
  • PMID: 9390536
  •     89 citations


Background: The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer.

Methods: Eligible patients (n = 2306) were randomly assigned to one of three treatment groups following surgery. A total of 771 patients with follow-up data received tamoxifen alone; 767 received methotrexate, fluorouracil, and tamoxifen (MFT); and 768 received cyclophosphamide, methotrexate, fluorouracil, and tamoxifen (CMFT). The Kaplan-Meier method was used to estimate disease-free survival, distant disease-free survival, and survival. Reported P values are two-sided.

Results: Through 5 years of follow-up, chemotherapy plus tamoxifen resulted in significantly better disease-free survival than tamoxifen alone (90% for MFT versus 85% for tamoxifen [P = .01]; 89% for CMFT versus 85% for tamoxifen [P = .001]). A similar benefit was observed in both distant disease-free survival (92% for MFT versus 87% for tamoxifen [P = .008]; 91% for CMFT versus 87% for tamoxifen [P = .006]) and survival (97% for MFT versus 94% for tamoxifen [P = .05]; 96% for CMFT versus 94% for tamoxifen [P = .03]). Compared with tamoxifen alone, MFT and CMFT reduced the risk of ipsilateral breast tumor recurrence after lumpectomy and the risk of recurrence at other local, regional, and distant sites. Risk of treatment failure was reduced after both types of chemotherapy, regardless of tumor size, tumor estrogen or progesterone receptor level, or patient age; however, the reduction was greatest in patients aged 49 years or less. No subgroup of patients evaluated in this study failed to benefit from chemotherapy.

Conclusions: Findings from this and other NSABP studies indicate that patients with breast cancer who meet NSABP protocol criteria, regardless of age, lymph node status, tumor size, or estrogen receptor status, are candidates for chemotherapy.

Where to go with new expensive treatments in NSCLC.
A Webb, M E O'Brien.
Br J Cancer, 1998 Jul 31; 78(2). PMID: 9683287    Free PMC article.
The place of chemotherapy in the treatment of early breast cancer.
A Buzdar.
Br J Cancer, 1998 Sep 19; 78 Suppl 4. PMID: 9741784    Free PMC article.
Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables.
G Tjeerdsma, M T Meinardi, +5 authors, D J van Veldhuisen.
Heart, 1999 Mar 27; 81(4). PMID: 10092570    Free PMC article.
Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
L B Michaud, A U Buzdar.
Drug Saf, 1999 Oct 08; 21(4). PMID: 10514021
Factors influencing the effect of age on prognosis in breast cancer: population based study.
N Kroman, M B Jensen, +3 authors, M Melbye.
BMJ, 2000 Mar 04; 320(7233). PMID: 10678859    Free PMC article.
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
R Saso, S Kulkarni, +7 authors, T Powles.
Br J Cancer, 2000 Jul 07; 83(1). PMID: 10883674    Free PMC article.
Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?
S J Jansen, J Kievit, +5 authors, A M Stiggelbout.
Br J Cancer, 2001 Jun 13; 84(12). PMID: 11401308    Free PMC article.
Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial.
C Focan, M Beauduin, +10 authors, Adjuvant Breast Cancer Project Belgium.
Br J Cancer, 2001 Jul 05; 85(1). PMID: 11437394    Free PMC article.
Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.
Jonathan Karnon, Jackie Brown, Adjuvant Breast Cancer (ABC) Steering Committee.
Pharmacoeconomics, 2002 Mar 13; 20(2). PMID: 11888364
Operable breast cancer.
M Cianfrocca, L J Goldstein.
Curr Treat Options Oncol, 2002 Jun 12; 2(2). PMID: 12057134
Early operable breast cancer.
A C Wolff, N E Davidson.
Curr Treat Options Oncol, 2002 Jun 12; 1(3). PMID: 12057163
Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm.
Christy A Russell.
Curr Oncol Rep, 2002 Dec 21; 5(1). PMID: 12493154
Oral ftorafur plus intramuscular thiotepa as adjuvant chemotherapy in patients with breast cancer.
C M Galmarini, C Garbovesky, D Galmarini, F C Galmarini.
Med Oncol, 2003 Jan 07; 19(4). PMID: 12512916
Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.
Xianglin L Du, Charles R Key, +2 authors, James S Goodwin.
Ann Intern Med, 2003 Jan 17; 138(2). PMID: 12529090    Free PMC article.
A candidate metastasis-associated DNA marker for ductal mammary carcinoma.
Patnala Mohan R Achary, Hui Zhao, +7 authors, Bhadrasain Vikram.
Breast Cancer Res, 2003 Mar 13; 5(2). PMID: 12631399    Free PMC article.
A role for antiangiogenic therapy in breast cancer.
Marsha A Moses, Jay Harper, Cecilia A Fernández.
Curr Oncol Rep, 2003 Dec 11; 6(1). PMID: 14664760
NSABP breast cancer clinical trials: recent results and future directions.
Eleftherios P Mamounas.
Clin Med Res, 2005 Jun 03; 1(4). PMID: 15931325    Free PMC article.
Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status.
Jeanne S Mandelblatt, Clyde B Schechter, +9 authors, Breast Cancer in Older Women Research Consortium.
J Gen Intern Med, 2005 Jul 01; 20(6). PMID: 15987322    Free PMC article.
Ipsilateral breast tumor recurrence after breast-conserving therapy: A comparison of quadrantectomy versus lumpectomy at a single institution.
Woo Chul Noh, Nam Sun Paik, +7 authors, Nan Mo Moon.
World J Surg, 2005 Jul 01; 29(8). PMID: 15988621
Clinical trial update: International Breast Cancer Study Group.
Karen N Price, Aron Goldhirsch, International Breast Cancer Study Group.
Breast Cancer Res, 2005 Nov 11; 7(6). PMID: 16280051    Free PMC article.
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
A Rocchi, S Verma.
Support Care Cancer, 2006 Apr 06; 14(9). PMID: 16596419
Heterogeneity of invasive ductal carcinoma: proposal for a hypothetical classification.
Baik-Hyeon Jo, Yi-Kyeong Chun.
J Korean Med Sci, 2006 Jun 17; 21(3). PMID: 16778390    Free PMC article.
The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer.
R A Nout, W E Fiets, +3 authors, J W R Nortier.
Breast Cancer Res Treat, 2007 Jul 31; 109(3). PMID: 17661169    Free PMC article.
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.
Alison K Conlin, Andrew D Seidman.
Mol Diagn Ther, 2007 Dec 15; 11(6). PMID: 18078353
Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.
Yasmine Nadler, Robert L Camp, +3 authors, Yuval Kluger.
Clin Cancer Res, 2008 Jul 17; 14(14). PMID: 18628459    Free PMC article.
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
James J Dignam, Vanja Dukic, +3 authors, Norman Wolmark.
Breast Cancer Res Treat, 2008 Oct 03; 116(3). PMID: 18830816    Free PMC article.
Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Douglas T Ross, Chung-Yeul Kim, +7 authors, Norman Wolmark.
Clin Cancer Res, 2008 Oct 18; 14(20). PMID: 18927301    Free PMC article.
Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.
Michael J Hassett, Melissa E Hughes, +7 authors, Jane C Weeks.
J Clin Oncol, 2008 Oct 29; 26(34). PMID: 18955448    Free PMC article.
Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.
Yu Shen, Wenli Dong, +3 authors, Sharon H Giordano.
Cancer, 2009 Mar 17; 115(10). PMID: 19288569    Free PMC article.
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
Stewart J Anderson, Irene Wapnir, +7 authors, Norman Wolmark.
J Clin Oncol, 2009 Apr 08; 27(15). PMID: 19349544    Free PMC article.
A new generalization of Weibull distribution with application to a breast cancer data set.
Abdus S Wahed, The Minh Luong, Jong-Hyeon Jeong.
Stat Med, 2009 May 09; 28(16). PMID: 19424958    Free PMC article.
Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.
Y Nadler, A M González, +3 authors, Y Kluger.
Ann Oncol, 2009 Sep 01; 21(3). PMID: 19717535    Free PMC article.
Adjuvant endocrine therapy for premenopausal women with breast cancer.
Shannon Puhalla, Adam Brufsky, Nancy Davidson.
Breast, 2009 Nov 17; 18 Suppl 3. PMID: 19914530    Free PMC article.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Venous thromboembolism and cancer: a systematic review.
Celso Arrais Rodrigues, Renata Ferrarotto, +2 authors, Paulo M G Hoff.
J Thromb Thrombolysis, 2010 Feb 09; 30(1). PMID: 20140479
Systematic Review.
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
Judy E Garber, Susan Halabi, +16 authors, Cancer and Leukemia Group B.
J Natl Cancer Inst, 2010 Jun 18; 102(13). PMID: 20554945    Free PMC article.
An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.
Xin Lu, Ke Zhang, +2 authors, Dimitri Semizarov.
BMC Med Genomics, 2010 Jun 24; 3. PMID: 20569491    Free PMC article.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy.
Andrew H Feifer, Jennifer M Taylor, Tatum V Tarin, Harry W Herr.
Eur Urol, 2011 Jan 25; 59(6). PMID: 21257257    Free PMC article.
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
Philippe L Bedard, Fatima Cardoso.
Nat Rev Clin Oncol, 2011 Mar 03; 8(5). PMID: 21364525
E2F1 and KIAA0191 expression predicts breast cancer patient survival.
Robin M Hallett, John A Hassell.
BMC Res Notes, 2011 Apr 02; 4. PMID: 21453498    Free PMC article.
Recent advances in the systemic therapy of breast cancer.
J T Cole.
Ochsner J, 2000 Jan 01; 2(1). PMID: 21765658    Free PMC article.
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.
Russell A Moore, Nelly Adel, +6 authors, Hani Hassoun.
J Clin Oncol, 2011 Aug 04; 29(25). PMID: 21810688    Free PMC article.
Practical implications of gene-expression-based assays for breast oncologists.
Aleix Prat, Matthew J Ellis, Charles M Perou.
Nat Rev Clin Oncol, 2011 Dec 07; 9(1). PMID: 22143140    Free PMC article.
Highly Cited. Review.
Clinical Significance of Age at the Time of Diagnosis among Young Breast Cancer Patients.
Im-Kyung Kim, Seho Park, +4 authors, Byeong-Woo Park.
J Breast Cancer, 2012 Feb 11; 14(4). PMID: 22323919    Free PMC article.
A hidden Markov model-based algorithm for identifying tumour subtype using array CGH data.
Ke Zhang, Yi Yang, +3 authors, Sens Donald.
BMC Genomics, 2012 Mar 06; 12 Suppl 5. PMID: 22369459    Free PMC article.
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?
Jeffrey G Schneider, Danny N Khalil.
Breast Cancer Res Treat, 2012 Jun 23; 134(3). PMID: 22723033    Free PMC article.
Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
Masoud H Manjili, Kayvan Najarian, Xiang-Yang Wang.
Future Oncol, 2012 Jul 07; 8(6). PMID: 22764768    Free PMC article.
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.
Shelby D Reed, Michaela A Dinan, Kevin A Schulman, Gary H Lyman.
Genet Med, 2012 Sep 15; 15(3). PMID: 22975761    Free PMC article.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
Gene expression profiling in breast cancer.
Belisario A Arango, Celine L Rivera, Stefan Glück.
Am J Transl Res, 2013 Apr 11; 5(2). PMID: 23573359    Free PMC article.
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
Meredith M Regan, Olivia Pagani, +12 authors, GroupSOFT and TEXT Investigators.
Breast, 2013 Oct 08; 22(6). PMID: 24095609    Free PMC article.
Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer.
Kimberly Mislick, Warren Schonfeld, Carolyn Bodnar, Kuo Bianchini Tong.
Clinicoecon Outcomes Res, 2014 Jan 29; 6. PMID: 24470765    Free PMC article.
The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience.
Eleftherios P Mamounas, Gong Tang, Qing Liu.
J Surg Oncol, 2014 Apr 15; 110(1). PMID: 24729388    Free PMC article.
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.
R Kreienberg, U-S Albert, +3 authors, A Wöckel.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(6). PMID: 24771925    Free PMC article.
The 21-gene recurrence score and locoregional recurrence in breast cancer patients.
Naresh K Jegadeesh, Sunjin Kim, +7 authors, Mylin A Torres.
Ann Surg Oncol, 2014 Dec 05; 22(4). PMID: 25472643    Free PMC article.
Risk of site-specific cancer in incident venous thromboembolism: a population-based study.
Tanya M Petterson, Randolph S Marks, +2 authors, John A Heit.
Thromb Res, 2014 Dec 31; 135(3). PMID: 25547213    Free PMC article.
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.
J Ribeiro, B Sousa, F Cardoso.
EJC Suppl, 2013 Sep 01; 11(2). PMID: 26217109    Free PMC article.
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
The Globalization of Cooperative Groups.
Manuel Valdivieso, Benjamin W Corn, +8 authors, Charles D Blanke.
Semin Oncol, 2015 Oct 05; 42(5). PMID: 26433551    Free PMC article.
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes.
Yehoda M Martei, Jennifer M Matro.
Breast Cancer (Dove Med Press), 2015 Oct 28; 7. PMID: 26504408    Free PMC article.
Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.
Ismail Jatoi, Hanna Bandos, +4 authors, Norman Wolmark.
J Natl Cancer Inst, 2015 Nov 01; 108(1). PMID: 26518884    Free PMC article.
Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
Andrew J Epstein, Yu-Ning Wong, +6 authors, Peter W Groeneveld.
J Clin Oncol, 2015 Nov 26; 33(36). PMID: 26598749    Free PMC article.
Chemotherapy in Premenopausal Breast Cancer Patients.
Ann H Partridge.
Breast Care (Basel), 2015 Dec 22; 10(5). PMID: 26688676    Free PMC article.
Antibody Therapeutics in Oncology.
Erik D Wold, Vaughn V Smider, Brunhilde H Felding.
Immunotherapy (Los Angel), 2016 Apr 16; 2(1). PMID: 27081677    Free PMC article.
The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Jessica G Cockburn, Robin M Hallett, +5 authors, Anita Bane.
BMC Cancer, 2016 Jul 30; 16. PMID: 27469239    Free PMC article.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.
Umair T Khan, Alex J Walker, +3 authors, Matthew J Grainge.
BMC Cancer, 2017 Nov 12; 17(1). PMID: 29126386    Free PMC article.
Systematic Review.
Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
Nita Amornsiripanitch, Vicky T Nguyen, +4 authors, Savannah C Partridge.
J Magn Reson Imaging, 2017 Nov 28; 48(1). PMID: 29178616    Free PMC article.
Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
Lu Zhang, Qingzhao Yu, +5 authors, Tekeda Ferguson.
Breast Cancer Res Treat, 2018 Jan 26; 169(1). PMID: 29368311    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
Charles E Geyer, Gong Tang, +8 authors, Norman Wolmark.
NPJ Breast Cancer, 2018 Nov 21; 4. PMID: 30456299    Free PMC article.
The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer.
Matti Aapro.
Biomed Hub, 2017 Nov 21; 2(Suppl 1). PMID: 31988928    Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
Jinani Jayasekera, Yisheng Li, +21 authors, CISNET-BOLD Collaborative Group.
J Natl Cancer Inst, 2018 May 03; 110(12). PMID: 29718314    Free PMC article.
Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
Jinani Jayasekera, Clyde B Schechter, +17 authors, CISNET-BOLD Collaborative Group.
J Natl Cancer Inst, 2018 Sep 22; 110(12). PMID: 30239794    Free PMC article.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2018 Nov 06; 125(2). PMID: 30387876    Free PMC article.
Drug Combinations in Breast Cancer Therapy.
Funmilola A Fisusi, Emmanuel O Akala.
Pharm Nanotechnol, 2019 Jan 23; 7(1). PMID: 30666921    Free PMC article.
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Manjiri M Bakre, Charusheila Ramkumar, +10 authors, Mark D Pegram.
Cancer Med, 2019 Mar 09; 8(4). PMID: 30848103    Free PMC article.
Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review.
Ang Zheng, Lin Zhang, +2 authors, Feng Jin.
Am J Mens Health, 2019 May 10; 13(3). PMID: 31068065    Free PMC article.
Potential Mechanisms of Cancer-Related Hypercoagulability.
Nicola J Nasser, Jana Fox, Abed Agbarya.
Cancers (Basel), 2020 Mar 04; 12(3). PMID: 32121387    Free PMC article.
Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer.
Jinani Jayasekera, Joseph A Sparano, +5 authors, Jeanne Mandelblatt.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337487    Free PMC article.
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
T M Aherne, M R Boland, +4 authors, K J Sweeney.
Surg J (N Y), 2020 Jun 25; 6(2). PMID: 32577529    Free PMC article.
Adjuvant chemotherapy for node negative, high Recurrence ScoreTM breast cancer: in defense of de-escalation.
Diana Lake, Andrew D Seidman.
NPJ Breast Cancer, 2019 Aug 21; 5. PMID: 31428677    Free PMC article.
Identification of a Six-lncRNA Signature With Prognostic Value for Breast Cancer Patients.
Erjie Zhao, Yujia Lan, +5 authors, Jing Hu.
Front Genet, 2020 Aug 28; 11. PMID: 32849766    Free PMC article.
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer.
Alice Labianca, Tommaso Bosetti, +2 authors, Roberto Francesco Labianca.
Cancers (Basel), 2020 Jul 31; 12(8). PMID: 32726933    Free PMC article.
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit.
Jinkyoung Kim, Aeree Kim, Chungyeul Kim.
Oncol Lett, 2019 Jan 25; 17(2). PMID: 30675242    Free PMC article.
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Thomas M Schwedhelm, Judy R Rees, +4 authors, Erika L Moen.
BMC Cancer, 2020 Sep 05; 20(1). PMID: 32883270    Free PMC article.